InMed Pharmaceuticals Inc. has announced the presentation of new preclinical data from its INM-901 program at the Alzheimer's Association International Conference $(AAIC)$ 2025. The study focuses on INM-901, a proprietary small molecule drug candidate targeting multiple biological pathways in Alzheimer's disease. The research highlights long-term treatment results in an advanced 5xFAD mouse model, demonstrating improvements in cognitive function, anxiety-related behavior, and sensory responsiveness. Key findings include INM-901's anti-inflammatory action, neuroprotective effects, and promotion of neuronal regeneration. The presentation is scheduled for the conference taking place from July 27-31, 2025, in Toronto, Canada, with a scientific poster detailing the study results. The data will be made available on InMed's website following the event.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.